Nvidia’s results, Indian tariffs, French markets - what’s moving markets
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced Monday that its board of directors has changed the location of the company’s 2025 Special Meeting of Stockholders. The meeting, which was originally scheduled to be held at 601 21st Street, Suite 300, Vero Beach, Florida, will now take place at 594 East Colorado Blvd., Suite 200, Pasadena, California.
The change was made by the board on Monday. Details regarding the date and time of the meeting remain as previously disclosed in the company’s proxy statement, which was filed on August 13, 2025, pursuant to Section 14(a) of the Securities Exchange Act of 1934.
Processa Pharmaceuticals is incorporated in Delaware and its common stock is listed on the Nasdaq Capital Market under the symbol PCSA.
This information is based on a statement from a press release included in the company’s recent filing with the U.S. Securities and Exchange Commission.
In other recent news, Processa Pharmaceuticals has announced a strategic investment and is exploring cryptocurrency treasury strategies to diversify its capital base. This move aims to enhance financial flexibility and support clinical development programs, potentially reducing shareholder dilution. The company has also successfully achieved a quorum for its Annual Shareholder Meeting, which will now be held on July 18 in Hanover, Maryland. H.C. Wainwright has reiterated a Buy rating on Processa Pharmaceuticals, setting a price target of $2.00, following the company’s recent portfolio update. The firm highlights the ongoing clinical development of Processa’s lead oncology asset, NGC-Cap, and plans for a new Phase 3 study for PCS499 in rare kidney diseases. Processa is establishing a subsidiary to manage PCS499, which could aid in capital raising and partnership opportunities. Earlier, the company’s annual meeting was adjourned due to a lack of quorum but is now set to proceed with sufficient proxy votes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.